Appointment of new Chairman of Redsense Medical’s Board of Directors

Eva Walde has been appointed Chairman of Redsense Medical’s Board of Directors until a new Chairman is elected by the Annual General Meeting. The appointment follows the deeply saddening passing of Redsense Medical’s former Chairman of the Board, Patrik Byhmer.

Eva Walde has been a valued member of Redsense Medical’s Board of Directors since 2023 and has over 30 years of experience in senior positions in pharmaceuticals, medical devices, diagnostics and biotechnology industries, mainly in marketing and sales. Eva currently serves on the Board of Directors of Sedana Medical AB, Senzime AB, Scale Up Life Science AB, Epigenica AB and FrostPharma AB.

Contact information

For more information, please contact: 
Pontus Nobréus, CEO
Telephone: +46 72-171 1264
E-mail: pontus.nobreus (at) redsensemedical.com

Redsense Medical AB (publ), 556646-4862

ABOUT REDSENSE MEDICAL

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS) and traded on OTCQX (RDSNF) in the US.